(Street) NEW YORK

NY

10106

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

X	Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
---	--

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL						
OMB Number:	3235-0287					
Estimated average burden						
hours per response:						

									Investmer				940							
1. Name and Address of Reporting Person* AISLING CAPITAL III LP					2. Issuer Name and Ticker or Trading Symbol <u>AGILE THERAPEUTICS INC</u> [AGRX]									5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director X 10% Owner						
(Last) (First) (Middle) 888 SEVENTH AVE., 12TH FLOOR					3. Date of Earliest Transaction (Month/Day/Year) 06/02/2016									Offic belo	er (give title w)		Other (below)	(specify		
000 01 1		., 1211112001																		
(Street) NEW YORK NY 10106				4. It	4. If Amendment, Date of Original Filed (Month/Day/Year)								Line	6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person X Form filed by More than One Reporting						
(City) (State) (Zip)																Pers	on			
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																				
1. Title of Security (Instr. 3) 2. Transac Date (Month/Da					Execution Date,			Code (Transaction Code (Instr.		5)			4 and Secur Benef Owne Report		cially I Following ted	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)	
										v	Amount		(A) (D)	or F	rice	Transaction(s) (Instr. 3 and 4)				
Common	Stock		h.l. 12		2/2016				J ⁽¹⁾⁽²⁾		400,				\$ <mark>0</mark>		2,583,797		Ι	See FN ⁽³⁾
		Та	ble II - I)						ired, D option							Owned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3. Deemed Execution Date, if any (Month/Day/Year) 3. Deemed Execution Date, (Month/Day/Year) 3. Deemed Execution Date, (Month/Day/Year) (Month/D		Transa Code (ransaction of E Code (Instr. Derivative (I		6. Date E Expiratio (Month/D	n Date	•	An Se Un De Se	Title and mount of ecurities nderlying erivative ecurity (Instr. nd 4)		Di Si (li	Price of erivative ecurity hstr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		11. Nature of Indirect Beneficial Ownership (Instr. 4)			
					Code	v	(A)	(D)	Date Exercisa		Expiratio Date	n Tit		Amou or Numb of Share:	er					
1. Name and Address of Reporting Person* AISLING CAPITAL III LP																				
(Last) 888 SEV	ENTH AVI	(First) E., 12TH FLOOF	(Midc R	lle)																
(Street) NEW YC	ORK	NY	1010)6		_														
(City)		(State)	(Zip)																	
1. Name and Address of Reporting Person* <u>Aisling Capital Partners III LLC</u>																				
(Last) 888 SEV	ENTH AVI	(First) E., 12TH FLOOF	(Mido R	lle)																
(Street) NEW YC	ORK	NY	1010	06		_														
(City)		(State)	(Zip)																	
1. Name and Address of Reporting Person* <u>Aisling Capital Partners III LP</u>																				
(Last) (First) (Middle) 888 SEVENTH AVE., 12TH FLOOR																				

(City)	(State)	(Zip)								
1. Name and Address of Reporting Person*										
ELMS STEVE										
(Last)	(First)	(Middle)								
C/O AISLING CAPITAL										
888 SEVENTH AVE., 12TH FLOOR										
(Street)										
NEW YORK	NY	10106								
(City)	(State)	(Zip)								
1. Name and Address of Reporting Person*										
Purcell Dennis	<u>s J</u>									
(Last) (First) (Middle)										
C/O AISLING CA	APITAL									
888 SEVENTH AVE., 12TH FLOOR										
(Street)										
NEW YORK	NY	10106								
(City)	(State)	(Zip)								
1. Name and Address of Reporting Person*										
SCHIFF ANDREW N										
(Last)	(Middle)									
C/O AISLING CAPITAL										
888 SEVENTH AVE., 12TH FLOOR										
(Street)	(Street)									
NEW YORK	NY	10106								
(City)	(State)	(Zip)								

Explanation of Responses:

1. On June 2, 2016, Aisling Capital III, LP ("Aisling") distributed 400,000 shares of Common Stock (the "Shares") of Agile Therapeutics, Inc. (the "Issuer") to its general and limited partners on a pro rata basis. Of the 400,000 Shares distributed by Aisling, Aisling Capital Partners III, LP ("Aisling GP") received its pro rata interest of 2,290 Shares, which it immediately distributed to its general and limited partners, including Aisling Capital Partners") and Dennis Purcell, Dr. Andrew Schiff and Steve Elms. Of the 2,290 Shares distributed by Aisling GP, Aisling Partners received its pro rata interest of 9 Shares, which it immediately distributed to its members, including Messrs. Elms, Purcell and Schiff. (cont'd in FN 2)

2. (cont'd from FN 1) As a result of such distributions by Aisling, Aisling GP and Aisling Partners, Messrs. Elms, Purcell and Schiff received (and now directly or indirectly hold) 961 Shares, 1,879 Shares and 460 Shares, respectively, in addition to the Shares held indirectly through Aisling.

3. The reportable securities are owned directly by Aisling, and held indirectly by Aisling GP, as general partner of Aisling, Aisling Partners, as general partner of Aisling GP, and each of the individual managing members of Aisling Partners. The individual managing members (collectively, the "Managers") of Aisling Partners are Dennis Purcell, Dr. Andrew Schiff and Steve Elms. Aisling GP, Aisling Partners and the Managers share voting and dispositive power over the shares directly held by Aisling.

Remarks:

Upon completion of the transactions reported herein, each of the Reporting Persons ceased to be 10% owners with respect to the Issuer. -- Exhibit List: 99.1 - Signatures of Joint Filers

See Signatures on Exhibit 99.1 06/03/2016

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FORM 4 JOINT FILER INFORMATION

Names of Joint Filers:

Aisling Capital III, LP Aisling Capital Partners III, LP Aisling Capital Partners III LLC Andrew N. Schiff, M.D. Dennis J. Purcell Steve Elms

Address of Joint Filers: c/o Aisling Capital Partners 888 Seventh Avenue New York, NY 10106

Designated Filer: Aisling Capital III, LP Issuer and Ticker Symbol: Agile Therapeutics, Inc. [AGRX] Date of Event: June 2, 2016 Signatures of Joint Filers:

AISLING CAPITAL III, LP

- By: Aisling Capital Partners III, LP General Partner
- By: Aisling Capital Partners III LLC General Partner
- By: /s/ Lloyd Appel Name: Lloyd Appel Title: CFO

AISLING CAPITAL PARTNERS III, LP

- By: Aisling Capital Partners III LLC General Partner
- By: /s/ Lloyd Appel Name: Lloyd Appel Title: CFO

AISLING CAPITAL PARTNERS III LLC

By: /s/ Lloyd Appel Name: Lloyd Appel Title: CFO

/s/ Andrew Schiff Andrew Schiff

/s/ Dennis Purcell

Dennis Purcell

/s/ Steve Elms

Steve Elms